Drug Type Small molecule-drug conjugates, Therapeutic radiopharmaceuticals |
Synonyms Etidronate-Re-188, Etidronate-Rhenium-188, Re-188-etidronate + [4] |
Target- |
Mechanism Osteoblasts inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC2H8O7P2Re |
InChIKeyIRNIPRCGJQWCNJ-NLQOEHMXSA-N |
CAS Registry145571-93-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Prostate Carcinoma | Phase 3 | NL | 16 May 2018 | |
Metastatic castration-resistant prostate cancer | Phase 3 | NL | 16 May 2018 | |
Castration-Resistant Prostatic Cancer | Phase 2 | CN | 15 Jun 2020 | |
Castration-Resistant Prostatic Cancer | Phase 2 | CN | 15 Jun 2020 |
Phase 1 | 12 | hdaazvlxgr(nurtbfjvno) = after the 2nd cycle of re-188 (thrombopenia grade 3 causing delay of the next cycle of treatment) wznqmiefwm (bljlxmsgpc ) | - | 20 May 2016 | |||
Not Applicable | 61 | fglrlpedzz(imjivjjkbz) = txkczoepvv ohzhecdjiu (vksjqfjsmd ) | Positive | 15 Jul 2004 |